服用恩瑞格需要注意什么事项？

(Deferasirox) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron anthelmintic approved by the US FDA for routine use. Generally speaking, Enrige can be taken for a long time. But there are a few things you need to pay attention to when taking Enrige dispersible tablets. Today we will learn more about what you need to pay attention to when taking Enrige?

1. Enriga (deferasirox) may cause rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication. If the situation is serious or persistent, the medication should be stopped. 2. The patient’s vision or hearing may be affected. 3. It should be taken 30 minutes before meals. Avoid combining Enrig with strong inducers of UDP-glucuronosyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors) and cholestyramine. Nor should it be administered with aluminum-containing antacids.

Deferasirox Dose Adjustments: Myelosuppression: Interrupt treatment; may restart once cause of cytopenias is determined; Contraindicated if platelet count <50,000/mm; Cutaneous Toxicity: Rash (severe): Interrupt treatment; may reintroduce at lower doses (with future dose escalations) and short-term oral corticosteroids. Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme): Stop and evaluate. Gastrointestinal: Discontinue treatment for suspected gastrointestinal ulceration or bleeding. Hearing loss or visual impairment: Consider dose reduction or treatment interruption.

Enrig (deferasirox) dispersible tablets are a new type of oral iron dispersant. It is the first oral iron dispersant that can be used routinely in the United States. It is approved for use in 2-year-old patients with chronic iron overload caused by blood transfusion. Clinical research is currently underway in China. Enrig is used to treat chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients older than 6 years old, and has the advantage of good treatment compliance. Enrig (deferasirox) is a ligand with three protrusions. Although the affinity of Enrig dispersible tablets to zinc and copper is very low, the concentrations of these trace metals in the serum still decreased to varying degrees after administration.

The above is the content of the precautions for (deferasirox), I hope it can help you!

Recommended related hot articles: /newsDetail/80952.html